News
Video
Author(s):
Caron A. Jacobson, MD, and Miguel-Angel Perales, MD, discuss different uses for CAR T-cell therapy, particularly a trial in which a CAR T-Cell therapy is being evaluated in MRD-positive patients treated with chemotherapy.
Blinatumomab Plus Consolidation Chemotherapy Extends OS in MRD– B-Cell Precursor ALL
Revisit the OncLive On Air Episodes From February 2024
Iopofosine I 131 Meets MRR End Point in R/R Waldenström Macroglobulinemia
Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma
Five-Year Follow-Up Data Confirm Long-Term Benefits of Olutasidenib in R/R IDH1+ AML
Odronextamab Elicits Durable Responses in Heavily Pretreated R/R Follicular Lymphoma
Dr Backhus on Surgical Eligibility in Borderline Resectable NSCLC
Dr Herbst on the Importance of Multidisciplinary Collaboration in NSCLC
Enhanced Clinical Education and Simplified Guidelines Needed to Address Germline Testing Gaps in Breast Cancer
Research Propels Additional Options into the Advanced HER2+ Breast Cancer Armamentarium